key: cord-0898751-eu02bczh authors: Wildwing, T.; Holt, N. title: Similarities between the neurological symptoms of COVID-19 and Functional Neurological Disorder: A systematic overview of systematic reviews and implications for future neurological healthcare services date: 2020-07-25 journal: nan DOI: 10.1101/2020.07.21.20158816 sha: 30ad2e06db582148badf9ddd84e2ec87745d1855 doc_id: 898751 cord_uid: eu02bczh Background COVID-19, a novel coronavirus, spread rapidly across the world from December 2019. While the main symptoms of the disease are respiratory, extensive research has realised evidence of a variety of neurological symptoms, both catastrophic such as cerebrovascular disease and benign such as hyposmia (loss of smell). Aim To provide health professionals with better accessibility to available evidence, this paper summarises findings from a systematic overview of systematic reviews of the neurological symptoms seen in patients with COVID-19. Similarities between the neurological symptoms of COVID-19 and Functional Neurological Disorder (FND) were explored and the impact of this on neurological services and health professionals' perceptions towards FND. Methods This research was completed in three phases: phase one, a systematic overview of current reviews of neurological symptoms of COVID-19 was conducted; phase two, the most common symptoms of FND defined within key sources were collated; phase three, the neurological symptoms of COVID-19 and those of FND were compared. Results Fourteen systematic reviews were identified within seven databases, published between 1st December 2019 and 15th June 2020. The results indicated (so far), that when compared, COVID-19 and FND exhibit many similar neurological symptoms. Conclusions This led to a consideration of the implications for neurological healthcare services in the UK, and the possible change-effect on perceptions of FND. Implications may include longer waiting times and a need for more resources (including more qualified health professionals). Future research is required to explore how health professionals' perceptions of neurological symptoms may change because of COVID-19. Coronavirus (COVID-19) has currently affected over twelve and a half million people worldwide. 1 COVID-19 has been found to cause neurological manifestations in up to 50% of patients. 2 The authors of this paper identified that many of these neurological symptoms appear similar to the symptoms of Functional Neurological Disorder (FND). This is 'the name given for symptoms in the body which appear to be caused by problems in the nervous system, but which are not caused by physical neurological disease or disorder'. 3 FND is deemed one of the most common sources of disability with prevalence ranging between 4 and 50 per 100,000 people, depending on measurement and type of FND. 45 As COVID-19 is so new, the potential similarities have not yet been explored in the literature. There is also limited research into the short and long-term effects of COVID-19 on medical and holistic neurological practice and where future resources will be required. To address these concerns, a systematic overview of systematic reviews was conducted. The aim was to summarise the neurological symptoms of COVID-19 and compare these symptoms with the symptoms of FND. This then led to consideration of the implications for neurological healthcare services in the UK and to the possible change-effect on perceptions of FND. Neurological services in the UK offer diagnosis and treatment to patients with diseases of the nervous system. 6 This research is therefore aimed at health professionals and commissioners in the field of neurology in the UK, informing future service provision for those who developed long-term neurological symptoms due to COVID-19, as well as exploring the effect of COVID-19 on health professionals' perceptions towards those with symptoms of FND. A systematic overview of current systematic reviews was conducted to explore: The potential impact of the longer-term neurological symptoms of COVID-19. The review protocol was not previously registered. The findings of this review were then compared with the symptom experiences of patients with FND. This research was completed in three phases: phase one, a systematic review of current reviews of neurological symptoms of COVID-19 was conducted; phase two, the most common symptoms of FND defined within key sources were collated; phase three the neurological symptoms of COVID-19 and those of FND were compared. The implications of these findings were then discussed. For phase one, the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement were followed (Fig 1 and Supplementary material). 7 The inclusion criteria consisted of systematic reviews only relating to neurological symptoms seen in patients with COVID-19 since 1 st December 2019. Both authors participated through each phase of the review independently (screening, eligibility and inclusion). Reviews were screened for relevancy against the inclusion criteria within title and abstract. Full-text reports for all potentially relevant reviews were obtained, including those where there was any uncertainty. The authors screened the full-text reports for relevancy and resolved any disagreement through discussions. Neither of the authors were blind to the journal titles, the authors' of the reviews or institutions. The Critical Appraisal Skills Programme (CASP) checklist for systematic reviews (2018) 8 was used to establish the quality of each review included within this systematic overview. All included reviews were deemed high quality; 9/10 of the CASP criteria were met by eight reviews, 8/10 were met by five reviews and 7/10 were met by one review. All reviews were read in full by both authors. Microsoft Excel was used to compile a list of all the included reviews and the neurological symptoms mentioned in each. This list was completed and checked by both authors. For phase two, a second systematic search was conducted of the same databases, with the same date restriction, using the following keywords: 'medically unexplained', 'MUPS', 'MUS', 'functional neurological', 'somatoform', 'psychogenic', 'review'. This search found 113 reviews relating to symptoms of FND. However, all were excluded after title and abstracts were screened for relevance. Therefore, four key sources were used to compile a summary of the common symptoms of FND, chosen as they were either certified by the NHS 91011 or the main accepted Diagnostic Manual for Mental Disorders. 12 For phase three, neurological symptoms of COVID-19 and FND were then placed into a table to compare the symptoms, which led to a consideration of the implications for neurological healthcare services in the UK, and to the possible change-effect on perceptions of FND. Phase 1: A systematic overview of systematic reviews of neurological symptoms of COVID-19 Figure 1 sets out the search strategy for the systematic overview. The database search identified 207 papers, with a further 13 papers identified within the reference lists. Of these 220 papers, 180 were excluded after title and abstract review for relevance. The remaining 32 papers were reviewed in full. 18 of these were excluded due to violation of inclusion criteria (date, study . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint design or methodology). 14 systematic reviews met the inclusion criteria and were included in this overview. The 14 systematic reviews were published between 11 th April 2020 and 9 th June 2020. Table 1 sets out the characteristics of the reviews; the number of studies reviewed within each review, relevant to this review and the number of participants in each relevant study. (Also in brackets, the total number of studies reviewed and the total number of participants in each review). The aims of each study are also included. As mentioned, the CASP checklist was utilised to check for risk of bias in each review. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. *Many reviews referenced the same studies, in some cases, reviews stated less studies were reviewed than were referenced with in the review, some studies did not state no. of participants As can be seen in Table 1 , some of the reviews explored issues outside the scope of this review. For example, some reviewers described neurological symptoms of other coronaviruses besides COVID-19 (e.g. Correia, 2020; Montalvan, 2020; Rogers, 2020). Within the scope of this review, 126 studies relating to neurological symptoms of COVID-19 were reviewed within the 14 reviews. Most of the reviews included the same studies. For instance, one study was included in all 14 reviews. 27 18,509 participants were included across the 126 studies reviewed. Table 2 shows the country where each reviewed study took place. As can be seen, a third of the studies took place in China (41 studies with a total of 5,794 participants). In addition, one study in South Korea investigated the neurological symptoms of COVID-19 of 3,191 participants, whilst Spain (five studies) and the UK (seven studies) also researched more than . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . 2,000 participants in each country. This gives an overview of the countries in which neurological symptoms of COVID-19 are under investigation, although it was not determined whether all participants were within the country stated. In addition, there may be publication bias as this review excluded reviews that were not in English. Throughout the 126 studies, 21 neurological symptoms were described. These are summarised in Table 3 below. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint Hyposmia and hypogeusia, changes to the senses of smell and taste, have been much discussed throughout the pandemic and have become key in aiding diagnosis of COVID-19. These symptoms were discussed in 39 studies within the 14 reviews, although it is worth noting that 20 of the studies were novel to a single review which specifically explored these symptoms. 28 Neurological manifestations of COVID-19 include catastrophic symptoms such as cardiovascular disease (CVD), encephalitis and Guillain-Barre Syndrome, which are understandably hugely concerning and have therefore generated intense discussion and research. As seen in Table 3 , COVID-19 has also been found to cause symptoms such as fatigue, dizziness and headache, which though more benign, can be disabling if they become chronic. The most common symptoms experienced by people with FND are presented in Table 4 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint DSM-5, the leading diagnostic manual for mental disorders, lists the symptoms of FND. However, on exploration it was found that key NHS sources list additional symptoms as can be seen in Table 4 . Only three of the 17 symptoms are listed in all four sources (shaded in grey). Some symptoms such as dizziness and facial pain are listed in only one source. The neurological symptoms of COVID-19 in Table 3 were compared with the neurological symptoms of FND in Table 4 . Table 5 shows this comparison. Neurological symptoms of COVID-19 include catastrophic symptoms requiring emergency care such as stroke, brain haemorrhage, encephalitis and Guillain-Barre Syndrome. However, 13 other neurological symptoms were shown to be similar in both COVID-19 and FND (shaded in grey within Table 5 ). In fact, except for hypogeusia, every non-catastrophic symptom of COVID-19, including the much-researched symptom of hyposmia, is also described as a symptom of FND. Furthermore, every symptom of FND, except bladder and bowel issues, hearing loss and swallowing problems, has been experienced by some people with COVID-19 neurological symptoms. These neurological symptoms, seen in both COVID-19 and FND, are the focus of this research, as if they become longer-term or chronic symptoms, they can be disabling and may require sustained support from within neurological healthcare services. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint 1) COVID-19 and FND present similar neurological symptoms COVID-19 and FND present similar neurological symptoms; every non-catastrophic symptom except for hypogeusia of COVID-19 is described as a symptom of FND. In addition, every symptom of FND, except bladder and bowel issues, hearing loss and swallowing problems, has been experienced by some people with COVID-19. As can be seen in Table 4 , key sources differ in their description of FND symptoms, indicating that there is no comprehensive list of all FND symptoms. It is likely that this contributes to health professionals' uncertainty in diagnosing FND. 29 On the other hand, COVID-19 can be quickly and easily diagnosed with a test (leaving aside the possibilities of false results). As academic journals and the media increasingly report neurological symptoms of COVID-19, it is feasible that patients who have had COVID-19 may attribute any neurological symptoms they have to the disease. Conversely, patients who develop FND now or in the future, may also attribute their symptoms to COVID-19, despite negative test results. The effects of these possibilities warrant further research. 2) The impact of these findings on neurological healthcare services The findings of this review highlight the effects that short and long-term neurological symptoms of COVID-19 may have on current neurological, and other, health services. Symptoms such as facial pain, muscle issues, neuralgia, fatigue and insomnia, which may become long term, may lead to an increase in demand for services such as pain, fatigue and sleep clinics. This is supported by other research which suggests rehabilitation required by patients following COVID-19 infection may be 'very much along the same lines' as existing services but with double the demand'. 30 As seen in Table 5 , fatigue is a symptom of both COVID-19 and FND. Consultant-led neurological services such as chronic fatigue clinics and headache clinics are already overstretched with a shortage of neurology consultants and long waiting lists. 31 Neurological symptoms of COVID-19 may increase demand for these clinics and may indicate a need for more qualified health professionals and specialists in neurology. However, the effects of COVID-19 on these services is hard to predict as the neuropathy, myopathy and sensory deficits of SARS resolved within three months of recovery 32 and COVID-19 may be similar. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07. 21.20158816 doi: medRxiv preprint Additionally, COVID-19 is causing a wider impact on patient populations. For example, COVID-19 has affected health care services, through reduction in use of emergency services during the peak of the pandemic in the UK as patients were worried about contracting the virus from hospitals. 33 There is evidence that some patients with long term conditions have improved their self-care techniques, such as better use of medication and alternative therapies such as physiotherapy, cognitive behavioural therapy, and exercise. 34 On the other hand, most outpatient appointments and elective surgeries were postponed, leading in some cases to deaths as an indirect result of COVID-19. 35 There are now questions about whether there will be a rebound in demand, potentially overwhelming NHS services, or whether the reduction in demand can be sustained. Combined with the previously mentioned potential increase in demand for neurological services, there is likely to be wide reaching financial implications. This research is therefore useful for aiding future patient management while helping to develop policies for response to COVID-19 and its critical outcomes. 36 3) The effect of COVID-19 on perceptions of FND The similarities between neurological symptoms of COVID-19 and FND are important to consider, providing education for health professionals, informing future practice and illustrating the need for more funding for neurological services to meet increased demand. Although large sums of money and research at pace, are contributing to a greater understanding of long-term symptoms of COVID-19 (for example, the UK Health and Social Care Secretary has announced the launch of a major £8.4 million research study into the long-term health effects of COVID-19 on hospitalised patients), 37 FND experiences a lack of funding and research into understanding, treatment and support for those who suffer from it. 38 FND may have lower prestige than COVID-19, as research has found that lower value is given to health professionals' role in managing poorly defined or unnamed symptoms. 39 In addition, FND, alongside other ambiguous uncertain conditions (e.g. fibromyalgia and chronic fatigue syndrome), is considered among the lowest conditions on the hierarchy of importance of conditions. 40 Furthermore, people with FND often feel health professionals do not believe their symptoms. 41 The realisation that COVID-19 causes neurological symptoms similar to FND may lead to a potential shift in perceptions in relation to FND. Due to this shift, FND may be taken more seriously, and more funding may be made available for neurological services. However, the authors of this research are concerned that the opposite . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint may occur: within neurological services priority may be given to patients who have had COVID-19, who may actually experience some level of prestige because they have survived a disease feared by all and any neurological symptoms they experience might be automatically accepted, extensively researched and supported, at detriment to FND. This skewing of services may have already begun as, alongside the research into long-term effects of COVID-19 previously mentioned, the NHS has declared its intention to provide a COVID-19 rehabilitation service. 42 Scientific reports centred on neurological effects of COVID-19 are still scarce, and risk of publication bias is high. For example, within the reviews included in this research, a third of the studies were undertaken in China and a further third in Europe and the USA combined. Despite the status of COVID-19 as a pandemic, this is not a worldwide review of the neurological effects of COVID-19. Additionally, this systematic review is grounding its results on previous studies' findings; thus it is difficult to assess how reliable some of these results can be, for example several of the articles did not state the source of their findings. Quality assessment has however been undertaken as described earlier and the reviews deemed high quality. Retrospective and prospective studies of larger cohorts are necessary to correctly assess nervous system involvement, which has not been possible yet for COVID-19 as it is a very new disease and it is unclear how much it mimics other coronaviruses. In conclusion, there is an array of evidence to show that COVID-19 causes neurological symptoms, although it is difficult to ascertain how long-term the symptoms may become. Although this paper is primarily UK focused, these concerns are likely to be similar in every country. This research collates the evidence so far and provides insight into the neurological effects of COVID-19 in relation to FND symptoms. Concerns about the potential impact of these findings on neurological and wider healthcare services are considered alongside the potential effect COVID-19 may have on perceptions of neurological symptoms, particularly . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint those relating to FND. Further research is recommended to explore whether the neurological symptoms of COVID-19 will improve acceptance and understanding of FND or whether this will worsen the experience for those who suffer from FND. Further thought for future planning of health care resources also needs to be taken into consideration, in light of this pandemic. This research received no grant from any funding agency in the public, commercial, or notfor-profit sectors. The authors declare that there is no conflict of interest. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint www.kingsfund.org.uk/press/press-releases/restarting-health-and-care-services-will-takemany-months (2020, accessed 10 July 2020). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2020. Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were prespecified. n/a 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. n/a 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2020. . https://doi.org/10.1101/2020.07.21.20158816 doi: medRxiv preprint How does Coronavirus Affect the Brain Do medically unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology outpatient clinics American Neuropsychiatric Association Committee for Research). Functional neuroanatomy and neurophysiology of functional neurological disorders (conversion disorder). The Journal of neuropsychiatry and clinical neurosciences Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Diagnostic and statistical manual of mental disorders Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis Central nervous system manifestations of COVID-19: A systematic review Neurological manifestations of COVID-19 and other coronaviruses: a systematic review Neuropsychiatric aspects of COVID-19 Pandemic: A Selective Review Neurological manifestations associated with COVID-19: a review and a call for action Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry Neurological involvement in SARS-CoV-2 infection: a clinical systematic review. Brain, Behavior, & Immunity-Health The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review Neurological manifestations and implications of COVID-19 pandemic. Therapeutic Advances in Neurological Disorders Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 Neurological impact of coronavirus disease (COVID-19): practical considerations for the neuroscience community Neurological manifestations of COVID-19: A review Coronavirus disease (COVID-19) in neurology and neurosurgery: A scoping review of the early literature Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis Dealing with the unknown. Functional neurological disorder (FND) and the conversion of cultural meaning Covid-19: the challenge of patient rehabilitation after intensive care Learning from the Elective Care Development Collaborative: Transforming elective care services neurology The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review Kings Fund, restarting health and care services will take months Nuffield Trust, where are the patients the factors affecting the use of emergency care during COVID-19 www.nuffieldtrust.org.uk/news-item/where-are-the-patients-the-factorsaffecting-the-use-of-emergency-care-during-covid-19 Nuffield Trust, where are the patients the factors affecting the use of emergency care during COVID-19 www.nuffieldtrust.org.uk/news-item/where-are-the-patients-the-factors-affectingthe-use-of-emergency-care-during-covid-19 Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International journal of infectious diseases Major study into long term health effects of Neurology Workforce Survey Conducted by the Association of British Neurologists Redefining quality: valuing the role of the GP in managing uncertainty Do diseases have a prestige hierarchy? A survey among physicians and medical students. Social science & medicine Are You Saying She's Mentally Ill Then?' Explaining Medically Unexplained Seizures in Clinical Encounters NHS to launch ground breaking online covid-9 rehab service International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity